Compare Quest Diagnostics Inc (DGX) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Kimberly Clark Corp — how do they compare? Quest Diagnostics Inc trades at $205.45 (market cap $22.80B), while Kimberly Clark Corp trades at $106.78 (market cap $35.46B). The key difference: Kimberly Clark Corp is the larger of the two by market cap, and Kimberly Clark Corp pays the higher dividend (4.79%). Which is the better fit depends on your goals.
| DGX | KMB | |
|---|---|---|
Market Cap | $22.80B | $35.46B |
Sector | Health | Consumer Staples |
52-Week High | $216.02 | $136.77 |
52-Week Low | $166.42 | $93.05 |
Enterprise Value | $28.82B | $42.00B |
Dividend Yield | 1.67% | 4.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $207.35, showing minimal daily movement with a slight decline of 0.04%. The stock maintains a bullish technical stance with recent earnings beats and analyst consensus pointing to upside potential. Recent developments include New York State approval for Haystack MRD testing and strong momentum across diagnostic channels. Revenue growth accelerated to $11.04 billion in 2025 with consistent profitability margins around 9%.
DGX presents a balanced investment case with 38% analyst buy ratings and a $227.75 price target suggesting 10% upside. The company demonstrates steady revenue growth and operational efficiency, though elevated debt levels and policy risks require monitoring. Second quarter earnings on July 23, 2026, will be crucial for validating current momentum and growth trajectory.
Kimberly-Clark (KMB) trades at $110.18, down 1.98% on the day, with strong technical support at $108 and resistance at $114. The company demonstrates solid fundamentals with Q1 2026 EPS beating expectations at $1.97 versus $1.93, maintaining a consistent earnings beat streak. Recent business developments include the Arbex joint venture launch and pending Kenvue acquisition, positioning for strategic growth in the consumer goods sector.
KMB offers stable dividend income with a 4.5% yield and strong profitability metrics (12.8% net margin, 146.29% ROE), though elevated P/E (21.31) and P/B (20.36) ratios suggest premium valuation. Risks include consumer sentiment pressures and input cost inflation, but analyst consensus targets $112.33 with 32% buy ratings supporting moderate upside potential from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
